Anticipates risks of tumor escape
Answers huge unmet need in solid tumors
2nd generation of innovative immuno-oncology
FDA Pre-IND passed
Top scientific leaders on board
GMP manufacturing ready
IP by design-platform strategy
Tailored first-in-class drugs design
Dynamic immuno-oncology market